Article Text
PDF
Abstract
Introduction/Background Research has indicated that obesity may have a modest association with the risk of ovarian cancer and it might interfere with tumour biology by resulting in more aggressive tumour microenvironment which may result in chemotherapy resistance altering the prognosis of the disease. In the present retrospective study we sought to determine whether obese patients have unfavourable survival outcomes.
Methodology The study was based on a retrospective chart review of patients operated for advanced EOC between 2016 and 2021. All patients that had maximal effort cytoreductive procedures (Surgical complexity score >4) were considered eligible. Body weight was evaluated with the BMI and subgrouping of patients was performed using the WHO classification for weight groups.
Results Overall, 94 women with epithelial OC were included in the present study. Of those, 65 women had high complexity score procedures, whereas the remaining had intermediate complexity score procedures. The median BMI of the cohort was 25 (18–47). 18 obese women (BMI>30) were identified. Obese patients were more likely to receive NACT (p=.034) and undergo less extensive surgery (p=.022). Median blood loss was comparable among obese and normal weight/overweight patients (p=.425) as well as the number of required transfusions (p=.402) for RBCs and (p=.858 )for FFP. The duration of hospitalisation although longer in obese patients, did not statistically differ (15 vs 6 days)(p=.284). Neither the rates of recurrence nor those of death differed among normal weight/overweight and obese women (p=.627). Similarly, the PFS 38 months (32–44) vs 40 months (24–55) (log-rank=.652) and the OS 44 months (26–61) vs 60 (35–84)(log-rank=.606) were comparable among the two groups of patients.
Conclusion Currently, it remains unknown if obese EOC patients have worse survival outcomes compared to non-obese patients. In our series differences were not significant, although obese patients were more likely to undergo intermediate complexity IDS rather than high complexity PDS.
Disclosures Nothing to disclose.
